DK308586A - Dna-sekvens, der koder for et specifikt protein, rekombinantvektor, der omfatter sekvensen, og celler, der er transficerede til ekspression af proteinet - Google Patents

Dna-sekvens, der koder for et specifikt protein, rekombinantvektor, der omfatter sekvensen, og celler, der er transficerede til ekspression af proteinet Download PDF

Info

Publication number
DK308586A
DK308586A DK308586A DK308586A DK308586A DK 308586 A DK308586 A DK 308586A DK 308586 A DK308586 A DK 308586A DK 308586 A DK308586 A DK 308586A DK 308586 A DK308586 A DK 308586A
Authority
DK
Denmark
Prior art keywords
protein
cells transfected
expression
recombinant vector
sequence encoding
Prior art date
Application number
DK308586A
Other languages
English (en)
Other versions
DK175574B1 (da
DK308586D0 (da
Inventor
Mark J Murray
Kathleen L Berkner
Donald C Foster
Earl W Davie
Original Assignee
Zymogenetics Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27115147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK308586(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/766,109 external-priority patent/US4968626A/en
Application filed by Zymogenetics Inc, Univ Washington filed Critical Zymogenetics Inc
Publication of DK308586D0 publication Critical patent/DK308586D0/da
Publication of DK308586A publication Critical patent/DK308586A/da
Application granted granted Critical
Publication of DK175574B1 publication Critical patent/DK175574B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK198603085A 1985-06-27 1986-06-27 DNA-sekvens, der koder for et specifikt protein, rekombinantvektor, der omfatter sekvensen, og celler, der er transficerede til ekspression af proteinet, samt fremgangsmåde til fremstilling af proteinet DK175574B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74960085A 1985-06-27 1985-06-27
US74960085 1985-06-27
US76610985 1985-08-15
US06/766,109 US4968626A (en) 1985-08-15 1985-08-15 DNA sequence coding for protein C

Publications (3)

Publication Number Publication Date
DK308586D0 DK308586D0 (da) 1986-06-27
DK308586A true DK308586A (da) 1986-12-28
DK175574B1 DK175574B1 (da) 2004-12-13

Family

ID=27115147

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198603085A DK175574B1 (da) 1985-06-27 1986-06-27 DNA-sekvens, der koder for et specifikt protein, rekombinantvektor, der omfatter sekvensen, og celler, der er transficerede til ekspression af proteinet, samt fremgangsmåde til fremstilling af proteinet

Country Status (7)

Country Link
EP (1) EP0215548B2 (da)
JP (2) JP2614848B2 (da)
AT (1) ATE93272T1 (da)
CA (1) CA1341228C (da)
DE (1) DE3688900T3 (da)
DK (1) DK175574B1 (da)
NO (1) NO305660B1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5550036A (en) * 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
USH1148H (en) 1987-04-17 1993-03-02 Method of separating activated human protein C
EP0296413A2 (en) * 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrid protein C and method for its preparation
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5196322A (en) * 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法
CA1332049C (en) * 1988-10-07 1994-09-20 Eli Lilly And Company Eukaryotic expression
AU6295390A (en) * 1989-08-11 1991-03-11 Zymogenetics Inc. Cell culture methods for producing activated protein c
JP2774156B2 (ja) * 1989-09-05 1998-07-09 帝人株式会社 ヒトプロテインｃおよび／または活性化ヒトプロテインｃ様活性を有する蛋白
JP2774163B2 (ja) * 1989-11-14 1998-07-09 帝人株式会社 ヒトプロテインｃ様活性を有する蛋白
AU7168591A (en) * 1989-12-29 1991-07-24 Zymogenetics Inc. Hybrid protein c
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
AT402263B (de) 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
EP0592692B1 (en) * 1992-05-01 1997-07-02 Teijin Limited Fed batch process for protein secreting cells
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
EP1237917A2 (en) * 1999-11-19 2002-09-11 Eli Lilly And Company Protein c derivatives
JP2009502118A (ja) * 2005-05-24 2009-01-29 アベスタゲン リミテッド 敗血症治療のための組み換え活性化ヒトタンパク質ｃを生成する方法
JP6460996B2 (ja) 2012-10-23 2019-01-30 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． ストレス測定システム

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327860D0 (en) * 1983-10-18 1983-11-16 Fujisawa Pharmaceutical Co Monoclonal antiprotein c antibody
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C

Also Published As

Publication number Publication date
JPH09107976A (ja) 1997-04-28
DE3688900T2 (de) 1993-12-09
DE3688900D1 (de) 1993-09-23
EP0215548B2 (en) 1998-01-07
JP2688407B2 (ja) 1997-12-10
EP0215548B1 (en) 1993-08-18
DK175574B1 (da) 2004-12-13
DK308586D0 (da) 1986-06-27
JPS62111690A (ja) 1987-05-22
NO862601L (no) 1986-12-29
EP0215548A1 (en) 1987-03-25
DE3688900T3 (de) 1998-06-10
ATE93272T1 (de) 1993-09-15
NO862601D0 (no) 1986-06-27
NO305660B1 (no) 1999-07-05
JP2614848B2 (ja) 1997-05-28
CA1341228C (en) 2001-05-15

Similar Documents

Publication Publication Date Title
DK308586A (da) Dna-sekvens, der koder for et specifikt protein, rekombinantvektor, der omfatter sekvensen, og celler, der er transficerede til ekspression af proteinet
NO874495L (no) Ekspresjon av protein c.
DE3688109D1 (en) Fsh.
NO963358D0 (no) Vertsvektor-system til anvendelse i genterapi
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
NO179106C (no) Fremgangsmåte for fremstilling av og ekspresjonssystem som koder for og kan uttrykke et rekombinant proteinkompleks med humanfaktor V111:C-aktivitet
DK127786D0 (da) Fremgangsmaade til fremstilling af tgf-beta, dna og mrna, som koder for tgf-beta, samt replicerbare vektorer omfattende dna'en og vaertscellerindeholdende vektorerne
ATE391175T1 (de) Multidrug resistenz gen
EP0835661A3 (en) Human interferon-Beta2A for use as a medicament
ES2078243T3 (es) Mejoras en o relativas a la expresion eucariotica.
EP0336383A3 (en) Novel recombinant human lymphotoxin
FI882238A0 (fi) Foerbaettringar i samband med organiska foereningar
EP0282512A4 (en) STABILIZATION OF MESSENGER RNA IN ANIMAL CELLS.
ATA435083A (de) Das polypeptid interleukin-2 kodierendes gen, rekombinante, dieses gen enthaltende dna, diese rekombinante dna aufweisende zellinien und verfahren zur herstellung von interleukin-2 unter verwendung der genannten zellen
AU6560886A (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells

Legal Events

Date Code Title Description
PUP Patent expired